View ValuationDr.Finance 将来の成長Future 基準チェック /06現在、 Dr.Financeの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長11.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 03Dr.Finance S.A., Annual General Meeting, Jun 26, 2026Dr.Finance S.A., Annual General Meeting, Jun 26, 2026, at 10:00 Central European Standard Time.お知らせ • May 27Dr.Finance S.A. to Report Fiscal Year 2025 Results on May 26, 2026Dr.Finance S.A. announced that they will report fiscal year 2025 results on May 26, 2026お知らせ • May 26+ 1 more updateDr.Finance S.A. to Report Q2, 2026 Results on Aug 13, 2026Dr.Finance S.A. announced that they will report Q2, 2026 results on Aug 13, 2026New Risk • May 25New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: zł2.4m (US$667k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (zł2.4m revenue, or US$667k). Market cap is less than US$10m (zł6.81m market cap, or US$1.87m).New Risk • May 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 40% per year over the past 5 years. Market cap is less than US$10m (zł4.94m market cap, or US$1.35m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Revenue is less than US$5m (zł9.4m revenue, or US$2.6m).New Risk • May 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 40% per year over the past 5 years. Market cap is less than US$10m (zł4.53m market cap, or US$1.26m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$5m (zł9.4m revenue, or US$2.6m).Reported Earnings • Oct 22Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł2.39m (down 7.2% from 3Q 2024). Net loss: zł106.8k (loss widened 2.8% from 3Q 2024).Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł2.40m (up 4.9% from 2Q 2024). Net income: zł130.2k (up zł274.4k from 2Q 2024). Profit margin: 5.4% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.Reported Earnings • May 17First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł2.12m (down 28% from 1Q 2024). Net loss: zł108.8k (loss widened 91% from 1Q 2024).Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł2.29m (up 88% from 2Q 2023). Net loss: zł144.2k (loss widened 248% from 2Q 2023).お知らせ • Jun 05Dr.Finance S.A., Annual General Meeting, Jun 28, 2024Dr.Finance S.A., Annual General Meeting, Jun 28, 2024.Reported Earnings • May 19First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł2.95m (up 296% from 1Q 2023). Net loss: zł57.0k (loss widened 400% from 1Q 2023).Reported Earnings • Feb 11Full year 2023 earnings released: zł0.002 loss per share (vs zł0.053 loss in FY 2022)Full year 2023 results: zł0.002 loss per share (improved from zł0.053 loss in FY 2022). Revenue: zł6.22m (down 17% from FY 2022). Net loss: zł7.7k (loss narrowed 96% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.お知らせ • Jan 12+ 4 more updatesDr.Finance S.A. to Report Fiscal Year 2023 Results on Nov 07, 2024Dr.Finance S.A. announced that they will report fiscal year 2023 results on Nov 07, 2024Reported Earnings • Nov 19Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł1.51m (down 1.2% from 3Q 2022). Net income: zł28.1k (up zł33.5k from 3Q 2022). Profit margin: 1.9% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 18Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł1.21m (down 43% from 2Q 2022). Net loss: zł41.4k (loss narrowed 47% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.お知らせ • Jun 13Dr.Finance S.A., Annual General Meeting, Jun 29, 2023Dr.Finance S.A., Annual General Meeting, Jun 29, 2023, at 12:00 Central European Standard Time.お知らせ • Jan 12+ 4 more updatesDr.Finance S.A. to Report Q4, 2022 Results on Feb 13, 2023Dr.Finance S.A. announced that they will report Q4, 2022 results on Feb 13, 2023お知らせ • Nov 15Dr.Finance S.A. to Report Q3, 2022 Results on Nov 15, 2022Dr.Finance S.A. announced that they will report Q3, 2022 results on Nov 15, 2022Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to zł1.04, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 18x in the Capital Markets industry in Poland. Total returns to shareholders of 234% over the past three years.お知らせ • Jun 02Dr.Finance S.A., Annual General Meeting, Jun 27, 2022Dr.Finance S.A., Annual General Meeting, Jun 27, 2022, at 10:00 Central European Standard Time.Reported Earnings • Apr 27First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł2.97m (up 54% from 1Q 2021). Net loss: zł72.1k (loss widened 107% from 1Q 2021).Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to zł1.09, the stock trades at a trailing P/E ratio of 26.4x. Average trailing P/E is 14x in the Capital Markets industry in Poland. Total returns to shareholders of 173% over the past three years.Reported Earnings • Feb 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: zł0.041 (up from zł0.004 loss in FY 2020). Revenue: zł11.7m (up 52% from FY 2020). Net income: zł154.5k (up zł168.0k from FY 2020). Profit margin: 1.3% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Jan 19Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to zł1.07, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 15x in the Capital Markets industry in Poland. Total returns to shareholders of 161% over the past three years.Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to zł1.30, the stock trades at a trailing P/E ratio of 34.3x. Average trailing P/E is 16x in the Capital Markets industry in Poland. Total returns to shareholders of 182% over the past three years.Valuation Update With 7 Day Price Move • Nov 22Investor sentiment improved over the past weekAfter last week's 21% share price gain to zł1.39, the stock trades at a trailing P/E ratio of 36.8x. Average trailing P/E is 15x in the Capital Markets industry in Poland. Total returns to shareholders of 202% over the past three years.Valuation Update With 7 Day Price Move • Oct 28Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to zł1.24, the stock trades at a trailing P/E ratio of 32.7x. Average trailing P/E is 14x in the Capital Markets industry in Poland. Total returns to shareholders of 187% over the past three years.Reported Earnings • Oct 19Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: zł3.49m (up 79% from 3Q 2020). Net income: zł191.4k (up 460% from 3Q 2020). Profit margin: 5.5% (up from 1.8% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 151 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 17First quarter 2021 earnings releasedThe company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: zł1.93m (up 12% from 1Q 2020). Net loss: zł34.9k (loss widened 166% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 124 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 17Full year 2020 earnings released: EPS zł0.012 (vs zł0.05 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: zł7.72m (up 7.5% from FY 2019). Net income: zł43.2k (down 77% from FY 2019). Profit margin: 0.6% (down from 2.6% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 51% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł1.37, the stock is trading at a trailing P/E ratio of 60.4x, up from the previous P/E ratio of 52.5x. This compares to an average P/E of 13x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 270%.Valuation Update With 7 Day Price Move • Jan 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to zł1.33, the stock is trading at a trailing P/E ratio of 58.7x, down from the previous P/E ratio of 70.6x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 217%.お知らせ • Jan 13+ 2 more updatesDr.Finance S.A. to Report Q3, 2021 Results on Oct 15, 2021Dr.Finance S.A. announced that they will report Q3, 2021 results on Oct 15, 2021Is New 90 Day High Low • Dec 28New 90-day high: zł1.73The company is up 281% from its price of zł0.45 on 29 September 2020. The Polish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 4.0% over the same period.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł1.73, the stock is trading at a trailing P/E ratio of 76.3x, up from the previous P/E ratio of 66.2x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 220%.Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 18% share price gain to zł1.49, the stock is trading at a trailing P/E ratio of 65.7x, up from the previous P/E ratio of 55.6x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 239%.Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 22% share price gain to zł1.50, the stock is trading at a trailing P/E ratio of 66.2x, up from the previous P/E ratio of 54.2x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 200%.Valuation Update With 7 Day Price Move • Dec 07Market bids up stock over the past weekAfter last week's 16% share price gain to zł1.28, the stock is trading at a trailing P/E ratio of 56.5x, up from the previous P/E ratio of 48.5x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 156%.Valuation Update With 7 Day Price Move • Nov 19Market pulls back on stock over the past weekAfter last week's 15% share price decline to zł1.05, the stock is trading at a trailing P/E ratio of 46.3x, down from the previous P/E ratio of 54.7x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 102%.Valuation Update With 7 Day Price Move • Nov 10Market bids up stock over the past weekAfter last week's 24% share price gain to zł1.23, the stock is trading at a trailing P/E ratio of 54.2x, up from the previous P/E ratio of 43.7x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 128%.Valuation Update With 7 Day Price Move • Nov 05Market bids up stock over the past weekAfter last week's 45% share price gain to zł1.41, the stock is trading at a trailing P/E ratio of 62.2x, up from the previous P/E ratio of 42.8x. This compares to an average P/E of 12x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 182%.Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 33% share price decline to zł1.10, the stock is trading at a trailing P/E ratio of 48.5x, down from the previous P/E ratio of 72.8x. This compares to an average P/E of 13x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 112%.Valuation Update With 7 Day Price Move • Oct 19Market bids up stock over the past weekAfter last week's 79% share price gain to zł1.65, the stock is trading at a trailing P/E ratio of 72.8x, up from the previous P/E ratio of 40.6x. This compares to an average P/E of 12x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 206%.Reported Earnings • Oct 15Third quarter earnings releasedOver the last 12 months the company has reported total profits of zł84.8k, down 53% from the prior year. Total revenue was zł7.29m over the last 12 months, up 5.8% from the prior year.Is New 90 Day High Low • Oct 12New 90-day high: zł0.92The company is up 109% from its price of zł0.44 on 14 July 2020. The Polish market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 6.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Dr.Finance は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測WSE:DRF - アナリストの将来予測と過去の財務データ ( )PLN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20262000N/A12/31/20255000N/A9/30/20259000N/A6/30/202510000N/A3/31/20259000N/A12/31/202410000N/A9/30/202411000N/A6/30/20249000N/A3/31/20248000N/A12/31/20236000N/A9/30/20234000N/A6/30/20234000N/A3/31/20235000N/A12/31/20227000N/A9/30/202210000N/A6/30/202212000N/A3/31/202213000N/A12/31/202112000N/A9/30/202110000N/A6/30/20219000N/A3/31/20218000N/A12/31/20208000N/A9/30/20207000N/A6/30/20207000N/A3/31/20207000N/A12/31/201970N/A0N/A9/30/201970N/A0N/A6/30/201960N/A0N/A3/31/201950N/A1N/A12/31/201850N/A0N/A9/30/201851N/A0N/A6/30/201851N/A0N/A3/31/201850N/A-1N/A12/31/201760N/A0N/A9/30/201760N/A0N/A6/30/201760N/A0N/A3/31/201760N/A0N/A12/31/201660N/A0N/A9/30/201650N/A1N/A6/30/201650N/A1N/A3/31/201650N/A0N/A12/31/201540N/A0N/A9/30/201540N/A0N/A6/30/20155-1N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: DRFの予測収益成長が 貯蓄率 ( 5.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: DRFの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: DRFの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: DRFの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: DRFの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: DRFの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/12 20:14終値2026/06/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Dr.Finance S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 03Dr.Finance S.A., Annual General Meeting, Jun 26, 2026Dr.Finance S.A., Annual General Meeting, Jun 26, 2026, at 10:00 Central European Standard Time.
お知らせ • May 27Dr.Finance S.A. to Report Fiscal Year 2025 Results on May 26, 2026Dr.Finance S.A. announced that they will report fiscal year 2025 results on May 26, 2026
お知らせ • May 26+ 1 more updateDr.Finance S.A. to Report Q2, 2026 Results on Aug 13, 2026Dr.Finance S.A. announced that they will report Q2, 2026 results on Aug 13, 2026
New Risk • May 25New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: zł2.4m (US$667k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (zł2.4m revenue, or US$667k). Market cap is less than US$10m (zł6.81m market cap, or US$1.87m).
New Risk • May 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 40% per year over the past 5 years. Market cap is less than US$10m (zł4.94m market cap, or US$1.35m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Revenue is less than US$5m (zł9.4m revenue, or US$2.6m).
New Risk • May 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 40% per year over the past 5 years. Market cap is less than US$10m (zł4.53m market cap, or US$1.26m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$5m (zł9.4m revenue, or US$2.6m).
Reported Earnings • Oct 22Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł2.39m (down 7.2% from 3Q 2024). Net loss: zł106.8k (loss widened 2.8% from 3Q 2024).
Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł2.40m (up 4.9% from 2Q 2024). Net income: zł130.2k (up zł274.4k from 2Q 2024). Profit margin: 5.4% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 17First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł2.12m (down 28% from 1Q 2024). Net loss: zł108.8k (loss widened 91% from 1Q 2024).
Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł2.29m (up 88% from 2Q 2023). Net loss: zł144.2k (loss widened 248% from 2Q 2023).
お知らせ • Jun 05Dr.Finance S.A., Annual General Meeting, Jun 28, 2024Dr.Finance S.A., Annual General Meeting, Jun 28, 2024.
Reported Earnings • May 19First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł2.95m (up 296% from 1Q 2023). Net loss: zł57.0k (loss widened 400% from 1Q 2023).
Reported Earnings • Feb 11Full year 2023 earnings released: zł0.002 loss per share (vs zł0.053 loss in FY 2022)Full year 2023 results: zł0.002 loss per share (improved from zł0.053 loss in FY 2022). Revenue: zł6.22m (down 17% from FY 2022). Net loss: zł7.7k (loss narrowed 96% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 12+ 4 more updatesDr.Finance S.A. to Report Fiscal Year 2023 Results on Nov 07, 2024Dr.Finance S.A. announced that they will report fiscal year 2023 results on Nov 07, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł1.51m (down 1.2% from 3Q 2022). Net income: zł28.1k (up zł33.5k from 3Q 2022). Profit margin: 1.9% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 18Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł1.21m (down 43% from 2Q 2022). Net loss: zł41.4k (loss narrowed 47% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 13Dr.Finance S.A., Annual General Meeting, Jun 29, 2023Dr.Finance S.A., Annual General Meeting, Jun 29, 2023, at 12:00 Central European Standard Time.
お知らせ • Jan 12+ 4 more updatesDr.Finance S.A. to Report Q4, 2022 Results on Feb 13, 2023Dr.Finance S.A. announced that they will report Q4, 2022 results on Feb 13, 2023
お知らせ • Nov 15Dr.Finance S.A. to Report Q3, 2022 Results on Nov 15, 2022Dr.Finance S.A. announced that they will report Q3, 2022 results on Nov 15, 2022
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to zł1.04, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 18x in the Capital Markets industry in Poland. Total returns to shareholders of 234% over the past three years.
お知らせ • Jun 02Dr.Finance S.A., Annual General Meeting, Jun 27, 2022Dr.Finance S.A., Annual General Meeting, Jun 27, 2022, at 10:00 Central European Standard Time.
Reported Earnings • Apr 27First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł2.97m (up 54% from 1Q 2021). Net loss: zł72.1k (loss widened 107% from 1Q 2021).
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to zł1.09, the stock trades at a trailing P/E ratio of 26.4x. Average trailing P/E is 14x in the Capital Markets industry in Poland. Total returns to shareholders of 173% over the past three years.
Reported Earnings • Feb 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: zł0.041 (up from zł0.004 loss in FY 2020). Revenue: zł11.7m (up 52% from FY 2020). Net income: zł154.5k (up zł168.0k from FY 2020). Profit margin: 1.3% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Jan 19Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to zł1.07, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 15x in the Capital Markets industry in Poland. Total returns to shareholders of 161% over the past three years.
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to zł1.30, the stock trades at a trailing P/E ratio of 34.3x. Average trailing P/E is 16x in the Capital Markets industry in Poland. Total returns to shareholders of 182% over the past three years.
Valuation Update With 7 Day Price Move • Nov 22Investor sentiment improved over the past weekAfter last week's 21% share price gain to zł1.39, the stock trades at a trailing P/E ratio of 36.8x. Average trailing P/E is 15x in the Capital Markets industry in Poland. Total returns to shareholders of 202% over the past three years.
Valuation Update With 7 Day Price Move • Oct 28Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to zł1.24, the stock trades at a trailing P/E ratio of 32.7x. Average trailing P/E is 14x in the Capital Markets industry in Poland. Total returns to shareholders of 187% over the past three years.
Reported Earnings • Oct 19Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: zł3.49m (up 79% from 3Q 2020). Net income: zł191.4k (up 460% from 3Q 2020). Profit margin: 5.5% (up from 1.8% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 151 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 17First quarter 2021 earnings releasedThe company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: zł1.93m (up 12% from 1Q 2020). Net loss: zł34.9k (loss widened 166% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 124 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 17Full year 2020 earnings released: EPS zł0.012 (vs zł0.05 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: zł7.72m (up 7.5% from FY 2019). Net income: zł43.2k (down 77% from FY 2019). Profit margin: 0.6% (down from 2.6% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 51% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł1.37, the stock is trading at a trailing P/E ratio of 60.4x, up from the previous P/E ratio of 52.5x. This compares to an average P/E of 13x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 270%.
Valuation Update With 7 Day Price Move • Jan 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to zł1.33, the stock is trading at a trailing P/E ratio of 58.7x, down from the previous P/E ratio of 70.6x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 217%.
お知らせ • Jan 13+ 2 more updatesDr.Finance S.A. to Report Q3, 2021 Results on Oct 15, 2021Dr.Finance S.A. announced that they will report Q3, 2021 results on Oct 15, 2021
Is New 90 Day High Low • Dec 28New 90-day high: zł1.73The company is up 281% from its price of zł0.45 on 29 September 2020. The Polish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 4.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł1.73, the stock is trading at a trailing P/E ratio of 76.3x, up from the previous P/E ratio of 66.2x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 220%.
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 18% share price gain to zł1.49, the stock is trading at a trailing P/E ratio of 65.7x, up from the previous P/E ratio of 55.6x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 239%.
Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 22% share price gain to zł1.50, the stock is trading at a trailing P/E ratio of 66.2x, up from the previous P/E ratio of 54.2x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 200%.
Valuation Update With 7 Day Price Move • Dec 07Market bids up stock over the past weekAfter last week's 16% share price gain to zł1.28, the stock is trading at a trailing P/E ratio of 56.5x, up from the previous P/E ratio of 48.5x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 156%.
Valuation Update With 7 Day Price Move • Nov 19Market pulls back on stock over the past weekAfter last week's 15% share price decline to zł1.05, the stock is trading at a trailing P/E ratio of 46.3x, down from the previous P/E ratio of 54.7x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 102%.
Valuation Update With 7 Day Price Move • Nov 10Market bids up stock over the past weekAfter last week's 24% share price gain to zł1.23, the stock is trading at a trailing P/E ratio of 54.2x, up from the previous P/E ratio of 43.7x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 128%.
Valuation Update With 7 Day Price Move • Nov 05Market bids up stock over the past weekAfter last week's 45% share price gain to zł1.41, the stock is trading at a trailing P/E ratio of 62.2x, up from the previous P/E ratio of 42.8x. This compares to an average P/E of 12x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 182%.
Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 33% share price decline to zł1.10, the stock is trading at a trailing P/E ratio of 48.5x, down from the previous P/E ratio of 72.8x. This compares to an average P/E of 13x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 112%.
Valuation Update With 7 Day Price Move • Oct 19Market bids up stock over the past weekAfter last week's 79% share price gain to zł1.65, the stock is trading at a trailing P/E ratio of 72.8x, up from the previous P/E ratio of 40.6x. This compares to an average P/E of 12x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 206%.
Reported Earnings • Oct 15Third quarter earnings releasedOver the last 12 months the company has reported total profits of zł84.8k, down 53% from the prior year. Total revenue was zł7.29m over the last 12 months, up 5.8% from the prior year.
Is New 90 Day High Low • Oct 12New 90-day high: zł0.92The company is up 109% from its price of zł0.44 on 14 July 2020. The Polish market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 6.0% over the same period.